用临床使用的抗病毒药物从胰腺细胞系中根除持续性柯萨奇 B 病毒感染。
Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs.
机构信息
Tampere University, Faculty of Medicine and Health Technology, Arvo Ylpönkatu 34, FIN-33520 Tampere, Finland.
Tampere University, Faculty of Medicine and Health Technology, Arvo Ylpönkatu 34, FIN-33520 Tampere, Finland.
出版信息
J Clin Virol. 2020 Jul;128:104334. doi: 10.1016/j.jcv.2020.104334. Epub 2020 Apr 26.
BACKGROUND
Persistent enterovirus infections create a difficult therapeutic challenge in immunocompromised patients and may also contribute to the development of chronic diseases including type 1 diabetes, cardiomyopathies, post-polio syndrome and chronic fatigue syndrome.
OBJECTIVES
To study the ability of antiviral drugs to eradicate such infection in vitro to evalaute their potential in the treatments of these patients.
STUDY DESIGN
We set out to evaluate several licensed or clinically tested drugs which have shown some anti-enterovirus activity in previous studies for their ability to cure persistent infection established by two different coxsackievirus B1 strains in a pancreatic cell line (PANC-1 cells).
RESULTS
Among all tested drugs Enviroxime, Fluoxetine, concentrated human IgG product (Hizentra) and Pleconaril were able to eradicate persistent Coxsackievirus B1 infection. The effect Enviroxime, Hizentra and Pleconaril varied between the two virus strains.
CONCLUSIONS
The identified drugs are feasible candidates for clinical trials among patients with persistent coxsackievirus B infections or chronic enterovirus-associated diseases.
背景
持续性肠道病毒感染给免疫功能低下的患者带来了治疗上的难题，也可能导致包括 1 型糖尿病、心肌病、脊髓灰质炎后综合征和慢性疲劳综合征在内的慢性疾病的发生。
目的
研究抗病毒药物在体外根除此类感染的能力，评估其在这些患者治疗中的潜力。
研究设计
我们评估了几种已获许可或经临床测试的药物，这些药物在先前的研究中显示出对肠道病毒有一定的活性，用于治疗两种不同柯萨奇病毒 B1 株在胰腺细胞系（PANC-1 细胞）中建立的持续性感染。
结果
在所有测试的药物中，Enviroxime、氟西汀、浓缩人免疫球蛋白产品（Hizentra）和普乐可复能够根除持续性柯萨奇病毒 B1 感染。Enviroxime、Hizentra 和普乐可复对两种病毒株的作用不同。
结论
所鉴定的药物是持续性柯萨奇病毒 B 感染或慢性肠道病毒相关疾病患者临床试验的可行候选药物。
Zotero 插件